Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

NCT ID: NCT01255891

Last Updated: 2024-12-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 46 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-01-31
• Study Completion Date: 2023-09-01

Brief Summary

To evaluate the efficacy of LHRH agonist with adjuvant pelvic radiation therapy in post radical prostatectomy patients with high risk pathological features for failure. To determine the freedom from biochemical (maintenance of a PSA less than nadir + 2 ng/ml) and clinical progression rate at 5 years.

Detailed Description

Same as brief Summary

Conditions

Adenocarcinoma of the Prostate

Keywords

high risk localized adenocarcinoma of the prostate

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Adjuvant

Adjuvant suppression plus radiation therapy

Group Type: OTHER

Androgen suppression plus radiation therapy

Intervention Type: RADIATION

Adjuvant androgen suppression plus radiation therapy

Interventions

Androgen suppression plus radiation therapy

Adjuvant androgen suppression plus radiation therapy

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

1. Adenocarcinoma of the prostate treated primarily with radical prostatectomy, pathologically proven to be lymph node negative by pelvic lymphadenectomy (N0) or lymph node status pathologically unknown (undissected pelvic lymph nodes [Nx]), i.e. lymph node dissection is not required;

2. Any type of radical prostatectomy will be permitted, including retropubic, perineal laparoscopic or robotically assisted. If performed, the number of lymph nodes removed per side of the pelvis and the extent of the pelvic lymph node dissection (obturator vs. extended lymph node dissection) should be noted. There is no time limit for the date of radical prostatectomy.

3. A post-radical prostatectomy entry PSA of > 0 and < 1 ng/ml at least 6 weeks after prostatectomy and within 30 days of registration.

4. One of the following pathologic/chemical classifications:

• T3N0/Nx disease with or without positive surgical margin; or;
• Gleason score of 8 or more;
• Pre prostatectomy PSA > 20 ng/ml

5. KPS > 70

6. Age ≥ 18;

7. No distant metastases, based upon the following minimum diagnostic workup:

8. History/physical examination (including digital rectal exam) within 8 wks prior to registration;

9. A CT scan or MRI of the abdomen and pelvis within 120 days prior to registration;

10. Bone scan within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis.

11. Adequate bone marrow function, within 90 days prior to registration, defined as follows:

• Platelets ≥ 100,000 cells/mm3 based upon CBC;
• Hemoglobin ≥ 10.0 g/dl based upon CBC
• AST or ALT < 2 x the upper limit of normal within 90 days prior to registration;

12. Patients must sign a study-specific informed consent prior to study entry.

Exclusion Criteria

1. A palpable prostatic fossa abnormality/mass suggestive of recurrence, unless shown by biopsy under ultrasound guidance not to contain cancer;

2. N1 patients are ineligible, as are those with pelvic lymph node enlargement ≥ 1.5 cm in greatest dimension by CT scan or MRI of the pelvis, unless the enlarged lymph node is sampled and is negative;

3. Androgen deprivation therapy started prior to prostatectomy for > 6 months duration;

4. Androgen deprivation therapy started after prostatectomy and prior to registration;

5. Prior pelvic radiotherapy;

6. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 5 years (for example, carcinoma in situ of the oral cavity is permissible);

7. Severe, active co-morbidity, defined as follows:

• History of inflammatory bowel disease;
• History of hepatitis B or C; Blood tests are not required to determine if the patient has had hepatitis B or C, unless the patient reports a history of hepatitis.
• Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;
• Transmural myocardial infarction within the last 6 months
• Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
• Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration;
• Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; AST or ALT are required; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol.
• Prior allergic reaction to the study drug(s) involved in this protocol.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

AbbVie (prior sponsor, Abbott)

INDUSTRY

Sponsor Role: collaborator

Dr. Tamim Niazi

OTHER

Sponsor Role: lead

Responsible Party

Dr. Tamim Niazi

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Tamim Niazi, MD

Role: PRINCIPAL_INVESTIGATOR

McGill University Department of Oncology

Locations

Montreal General Hospital

Montreal, Quebec, Canada

Jewish General Hospital

Montreal, Quebec, Canada

Countries

Canada

References

Elakshar S, Tolba M, Tisseverasinghe S, Pruneau L, Di Lalla V, Bahoric B, Niazi T. Salvage Whole-Pelvic Radiation and Long-Term Androgen-Deprivation Therapy in the Management of High-Risk Prostate Cancer: Long-Term Update of the McGill 0913 Study. Curr Oncol. 2023 Aug 1;30(8):7252-7262. doi: 10.3390/curroncol30080526.

Reference Type: DERIVED

PMID: 37623007 (View on PubMed)

Kucharczyk MJ, Tsui JMG, Khosrow-Khavar F, Bahoric B, Souhami L, Anidjar M, Probst S, Chaddad A, Sargos P, Niazi T. Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study. Front Oncol. 2020 Mar 12;10:312. doi: 10.3389/fonc.2020.00312. eCollection 2020.

Reference Type: DERIVED

PMID: 32226774 (View on PubMed)

Other Identifiers

McG 0913

Identifier Type: -

Identifier Source: org_study_id